Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | SLC6A7 | Q99884 | 6/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4415954 | 0.91 | ALDH1A1 (0.62) | KDM4EALDH1A1LMNAHPGD | |
| SCHEMBL4315496 | 0.89 | ALDH1A1 (0.48) | KDM4ESLC6A7HTTALDH1A1HPGD | |
| SCHEMBL4317911 | 0.87 | L3MBTL1 (0.57) | KDM4ESLC6A7ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL4314270 | 0.87 | KDM4E (0.56) | KDM4ESLC6A7ALDH1A1TSHRLMNA | |
| SCHEMBL4324183 | 0.87 | ALDH1A1 (0.56) | KDM4ESLC6A7ALDH1A1HPGD | |
| SCHEMBL4324240 | 0.86 | KIT (0.49) | KDM4EALDH1A1LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL4417361 | 0.86 | SLC6A7 (0.56) | KDM4ESLC6A7ALDH1A1LMNAHPGD | |
| SCHEMBL4419706 | 0.86 | KIT (0.52) | KDM4EALDH1A1LMNAL3MBTL1HPGD | |
| SCHEMBL4326377 | 0.85 | SLC6A7 (0.58) | KDM4ESLC6A7ALDH1A1TSHRLMNA | |
| SCHEMBL4428020 | 0.84 | KIT (0.47) | KDM4EHTTALDH1A1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | claimed |
| WO-2009143404-A1 | PIPERAZINE METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) NEGATIVE ALLOSTERIC MODULATORS FOR ANXIETY/DEPRESSION | WYETH (US) | 2009-11-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | KDM4E 1411/4885SLC6A7 234/4885HTT 1727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.